Edge Rewrite
everything Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a4494bbe1f3ccf3f

Jump to content

Draft:Perspective Therapeutics

From Wikipedia, the free encyclopedia

Perspective Therapeutics, Inc. is an American clinical-stage radiopharmaceutical company headquartered in Seattle, Washington. It develops targeted alpha-particle treatments for cancer based on lead-212, along with lead-203 compounds for diagnostic imaging.[1][2][3] The company is traded on the NYSE American under the ticker symbol CATX.[2]

History

[edit]

Viewpoint Molecular Targeting was a radiopharmaceutical developer based in Coralville, Iowa, that originated as a University of Iowa spinout.[4] In September 2022, Viewpoint agreed to merge with Isoray, a publicly traded maker of cesium-131 brachytherapy seeds. The merger closed in February 2023, with Viewpoint becoming a wholly owned subsidiary of Isoray; Isoray then changed its name to Perspective Therapeutics and its stock symbol from ISR to CATX.[5][6]

In December 2023, Perspective agreed to sell the cesium-131 business of its Isoray subsidiary to GT Medical Technologies. The transaction closed in April 2024.[7][8][2]

Research and development

[edit]

Lead-212 decays through alpha-emitting daughter isotopes. Lead-203 can be attached to a corresponding targeting compound for SPECT imaging.[9][3] A 2025 paper reported initial clinical experience in 12 patients with metastatic neuroendocrine tumors, who underwent lead-203 imaging followed, where eligible, by lead-212 treatment.[3]

As of September 2026, Perspective's clinical programs included lead (²¹²Pb) bamzireotide navoxetan (VMT-α-NET), which targets somatostatin receptor 2 in neuroendocrine tumors;[10][11] lead (²¹²Pb) lapemelanotide zapixetan (VMT01), which targets melanocortin 1 receptor in melanoma;[10][12][13] and PSV359, which targets fibroblast activation protein alpha in solid tumors.[14] The studies were in Phase 1/2a development.[2][15]

Perspective arranged for Bristol Myers Squibb to supply nivolumab for a VMT01 combination study.[16] In September 2026, it announced a similar drug-supply arrangement with Merck for a planned PSV359 and pembrolizumab combination arm.[17]

Manufacturing

[edit]

Perspective obtains thorium-228 under a U.S. Department of Energy supply agreement and uses a generator system to produce lead-212 for its investigational treatments.[2] In March 2024, it acquired the assets and associated lease of a radiopharmaceutical manufacturing facility in Somerset, New Jersey.[15] It has supplied clinical trials from manufacturing sites in Coralville, Iowa, and Somerset, New Jersey.[15] The company has cited lead-212's short half-life as a reason for developing a geographically distributed production network.[18] As of 2026, the company was expanding this network with additional sites in the Chicago and Los Angeles metropolitan areas, with the Chicago-area facility expected to be completed in 2027.[15]

References

[edit]
  1. ↑ Samorodnitsky, Dan (June 6, 2025). "Perspective Therapeutics Brings Energy to the Radiopharma World". BioSpace. https://www.biospace.com/drug-development/perspective-therapeutics-brings-energy-to-the-radiopharma-world
  2. 1 2 3 4 5 Perspective Therapeutics, Inc. Annual Report on Form 10-K for the year ended December 31, 2025 (filed 2026). U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/728387/000072838726000004/catx-20251231.htm
  3. 1 2 3 Michler, Enrico; et al. (2025). "[203/212Pb]Pb-VMT-α-NET as a novel theranostic agent for targeted alpha radiotherapy—first clinical experience". European Journal of Nuclear Medicine and Molecular Imaging 52: 4171–4183. doi:10.1007/s00259-025-07269-0.
  4. ↑ University of Iowa, Office of the Vice President for Research (August 31, 2016). "UI-spinout Viewpoint Molecular Targeting finalist in national university startup competition". https://research.uiowa.edu/news/2016/08/ui-spinout-viewpoint-molecular-targeting-finalist-national-university-startup
  5. ↑ Isoray, Inc. Current Report on Form 8-K, filed February 6, 2023 (completion of the merger with Viewpoint Molecular Targeting on February 3, 2023). U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/728387/000143774923002543/isr20230204_8k.htm
  6. ↑ Lohman, John (February 8, 2023). "Medtech companies merge to form Perspective Therapeutics". Corridor Business Journal. https://corridorbusiness.com/medtech-companies-merge-to-form-perspective-therapeutics/
  7. ↑ "GT Medical Technologies inks supply deal with Perspective Therapeutics". AuntMinnie. December 12, 2023. https://www.auntminnie.com/clinical-news/radiation-oncology-therapy/article/15660040/gt-medical-technologies-inks-supply-deal-with-perspective-therapeutics
  8. ↑ "GT Medical completes acquisition of Isoray Medical cesium-131 assets". AuntMinnie. April 15, 2024. https://www.auntminnie.com/clinical-news/radiation-oncology-therapy/article/15668623/gt-medical-completes-acquisition-of-isoray-medical-cesium131-assets
  9. ↑ Scaffidi-Muta, Jarred Michael; Abell, Andrew David (2025). "212Pb in targeted radionuclide therapy: a review". EJNMMI Radiopharmacy and Chemistry 10. doi:10.1186/s41181-025-00362-7.
  10. 1 2 World Health Organization (2025). "International Nonproprietary Names for Pharmaceutical Substances (INN): Recommended INN List 93". WHO Drug Information. https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/rl93.pdf
  11. ↑ ClinicalTrials.gov. "Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors". NCT05636618. https://clinicaltrials.gov/study/NCT05636618
  12. ↑ Orcutt, Karen D.; et al. (2022). "Dosimetry of [212Pb]VMT01, a MC1R-Targeted Alpha Therapeutic Compound, and Effect of Free 208Tl on Tissue Absorbed Doses". Molecules 27 (18): 5831. doi:10.3390/molecules27185831.
  13. ↑ ClinicalTrials.gov. "MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma". NCT05655312. https://clinicaltrials.gov/study/NCT05655312
  14. ↑ ClinicalTrials.gov. "Lead-212 PSV359 Therapy for Patients With Solid Tumors". NCT06710756. https://clinicaltrials.gov/study/NCT06710756
  15. 1 2 3 4 Perspective Therapeutics, Inc. Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/728387/000119312526342512/catx-20260630.htm
  16. ↑ Perspective Therapeutics (March 18, 2024). "Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate VMT01 with Nivolumab". https://perspectivetherapeutics.com/pr/perspective-therapeutics-announces-clinical-collaboration-agreement-with-bristol-myers-squibb-to-evaluate-212pbvmt01-in-combination-with-nivolumab-in-mc1rpositive-metastatic-melanoma
  17. ↑ Perspective Therapeutics (September 14, 2026). "Clinical Collaboration and Supply Agreement with Merck to Evaluate PSV359 with Pembrolizumab". https://perspectivetherapeutics.com/pr/perspective-therapeutics-announces-clinical-collaboration-and-supply-agreement-with-merck-to-evaluate-212pbpsv359-in-combination-with-keytruda-pembrolizumab-in-fap-positive-solid-tumors
  18. ↑ Lundin, Andy (September 8, 2026). "Radiopharma’s growing pipeline puts capacity to the test". Pharma Manufacturing. https://www.pharmamanufacturing.com/facilities/facility-design-management/article/55403416/radiopharmas-growing-pipeline-puts-capacity-to-the-test
Retrieved from "https://en.wikipedia.org/w/index.php?title=Draft:Perspective_Therapeutics&oldid=1377747408"